HAV/HBV Flashcards

1
Q

Acute vs Chronic Hepatitis

A
  • All viral hepatitis causes acute infections and some cause chronic (lasts >6 mo)
  • Likelihood of developing chronic infection also depends on immune system, age, infectious agent, etc
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Hepatitis + Symptoms

A
  • No differentiating symptoms between different viral hepatitis
  • Symptoms: fever, fatigue, loss of appetite, N/V, pain, dark urine, joint pain, hepatosplenomegaly
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Hepatitis A

A
  • Non-enveloped RNA virus known as a picornavirus
  • Acute infection only
  • Most recover and have lifelong immunity but it can cause fulminant hepatitis and death
  • Most children <6 y.o. are asymptomatic
  • > 6 y.o. is most likely to experience jaundice
  • Incubation: ~28 days
  • Can survive outside the body for months (extreme heat kills)
  • Infectivity peaks 2 weeks before and 1 week after symptoms begin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Hep A Transmission

A
  • Poor sanitation, poor hygiene, contaminated food/water
  • HAV shed in stool is primary spread via food/water contamination with infected fecal matter
  • If good sanitation/safe water, seen more with injection drug use, male homosexual intercourse, travel to countries with high HAV rates
  • Adequate chlorination of of water kill HAV in water
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Hep A Lab Diagnosis

A
  • Elevated anti-HAV for identifying acute HAV (5-10 days post-exposure)
  • Total anti-HAV includes IgM an IgG and doesn’t differentiate between acute and previous infection
  • Elevated aminotransferase (ALT > AST), bilirubin (occurs second to ALT/AST), and alkaline phosphatase are also seen but connected to general hepatitis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

HAV Prevention

A
  • Vaccination! - long term
  • Monovalent vaccines inactivated, no preservative, given IM
  • Seroconversion >=94% with first dose but booster recommended for maximal titers
  • Don’t restart interrupted series
  • Travelers should get first dose as soon as travel is considered
  • Need at least 1 dose at least 1 mo before exposure to avoid pre/post prophylaxis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

HAV Vaccination Recommended Groups

A
  • All children at least 1 y.o.
  • Children 2-18 y.o. living in state/community where routine Hep A vaccination is implemented from high incidence
  • Travel/work in countries with high/moderate endemicity
  • MSM
  • IDU
  • Occcupational risk
  • Clotting factor disorders patients
  • Chronic liver disease patients
  • International adoptions from at risk countries
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

HAV + Immunoglobulin

A
  • Used if vaccine can’t be used
  • Provide passive transfer of antibody to body
  • Most effective if given during incubation period
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Hep A Immunoglobulin Groups

A
  • Children <12 mo
  • Adults > 40 y.o.
  • Immunocompromised
  • Hemodialysis
  • Chronic liver disease
  • Allergy to vaccine/vaccine component
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Hepatitis B

A
  • Transmitted via percutaneous or mucosal contact with infectious blood/fluids
  • Survives outside body at least 7 days
  • Incubation: ~90 days
  • Often occurs < 40 y.o. and in absence of cirrhosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Hep B Presentation

A
  • Signs/symptoms vary by age
  • Most immunosuppressed adults and kids <5 y.o. are asymptomatic
  • 30-50% of those >=5 y.o. have initial symptoms
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Hep B Risk Groups

A
  • High prevalence HBsAg areas
  • Infants born to infected mothers
  • Contacts with chronic HBV infected persons
  • IDU
  • Sexually active non-monogomous long-term relationships
  • MSM
  • Health care/public safety wrokers
  • Residents/staff at disabled persons facilities
  • Chronic liver disease and hemodialysis patients
  • Travel to risk areas
  • Immunocompromised
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

HBV Infection Course

A
  • DNA virus that becomes part of host DNA
  • Active or inactive phases
  • Active infection requires treatment evaluation depending on ongoing liver injury
  • Risk HBV disease progression is based on HBV serologies
  • ~30% will develop cirrhosis
  • Can develop liver cancer at ANY point in infectious process
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Common HBV Serology Tests

A
  • HBsAg: protein found on surface of HBV and is detectable in acute or chronic infection
  • anti-HBs: antibody produced after a successful vaccine series
  • Total anti-HBc: indicates prior or ongoing infection, negative with lack of immunization, includes IgM and IgG

IgM = < 6mo (recent infection), IgG > 6 mo (prior infection)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Other HBV Serology Tests

A
  • HBeAg: present during active viral replication

- anti-HBe: formed in response to HBeAg and is present during antiviral therapy, predictor of long-term HBV clearance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

HBV Prevention

A
  • Vaccination
  • Single antigen and combination antigen options
  • 3 series, no maximum time between doses
17
Q

HBV Vaccination Pearls

A
  • 2nd and 3rd dose should be at least 8 weeks apart
  • Not harmful to get extra doses
  • Ok to give with other vaccines
  • 2 dose series approved for 11-15 y.o.
  • 30-50% protection with dose 1, 75% with dose 2, 96% with dose 3
  • Lower protection seen in smokers, elderly, immunosuppressed, obese
18
Q

Heplisav-B

A
  • New HBV vaccine
  • Utilizes new adjuvant for more robust response
  • Given as 2 doses, 1 mo apart for >=18 y.o.
  • Higher seroprotection rates in various populations compared to traditional Engerix dosing
19
Q

HBV + Immunoglobulin

A
  • Passive protection to prevent perinatal transmission
  • Required to give to infants within 24 hours of birth to reduce transmission from HBV positive moms
  • Not routinely used for adults
20
Q

HBV Vaccination Recommendations

A
  • Pediatric patients at birth, <19 y.o.
  • At risk for sexual exposure (MSM, non-monogamous)
  • At risk for percutanous, mucosal, or blood exposure (jail, dialysis, health care, disabled, immunosuppressed)
  • International travelers
  • Chronic liver disease patients
  • HIV positive
21
Q

When to Treat HBV

A
  • HBV >= 2000 and ALT at UNL, recommend to treat

- Treat all cirrhotic patients

22
Q

HBV Goals of Therapy

A
  • Long term suppression of HBV virus
  • Induction of HBeAg loss (not actively replicating)
  • Normalizing ALT levels (not being actively inflammed/changed)
23
Q

HBV Preferred Treatments

A
  • Interferons
  • Entecavir
  • Tenofovir
24
Q

Interferons

A
  • Immune modulating protein
  • Causes lots of SE and risk of decompensation
  • Rarely to never used
25
Q

Entecavir

A
  • Nucleoside analogue inhibits HBV polymerase and activity against HIV
  • 0.5 mg in treatment naive or non-lamivudine resistant infections
  • 1mg in lamivudine refractory patients
  • Safe in cirrhotic patients
26
Q

Tenofovir

A
  • Nucleotide analog with activity against HBV and HIV
  • TAF or TDF
  • TDF 300 mg PO daily, renal adjustment
  • TAF: 25 mg PO daily
  • Safe in cirrhotic patients
27
Q

HBV Non-preferred Therapies

A
  • All safe in cirrhosis, but limited use due to resistance concerns
  • Adefovir: nucleoside analog to inhibit HBV, some HIV activity
  • Lamivudine: nucleoside analog with HIV and HBV activity, good for immunosuppressed, resistance w/ >5 years of use
  • Telbivudine: nucleoside analog for HBV specifically
28
Q

Immunosuppresed + HBV

A
  • Start prophylaxis before immunosuppressive therapies
  • Give vaccine if susceptible
  • Can monitor instead of prophylaxis: check HBV DNA levels during and for 12 mo after cessation of therapy
  • Test for serologic levels to see if at risk for reactivation
29
Q

HIV + HBV

A
  • Test all for HIV before starting HBV treatment
  • Can use antivirals that work for both
  • If not needing HAART for HIV, use HBV specific meds to minimize resistance development to HIV medications
30
Q

Pregnancy + HBV

A
  • High risk of transmission during delivery, especially with high viral loads
  • Give mother lamivudine or tenofovir to decrease risk
  • HBV vaccination and immunoglobulin for passive and active protection for newborn given at birth